No NK -No future

Discussion in 'Oyster Point Pharma' started by anonymous, Mar 18, 2023 at 8:54 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    So we don’t have any more studies going on for early NK. We will focus on a more severe N K, and the trials haven’t even begun yet. The science, though exciting is totally unproven and a long ways away. Is anybody excited about mydryasis reversal? No I don’t think so. Docs could care less, they use a 2hour dilating drop as it is so reversal needs are minimal. The presbyopia market is dying on the vine. There will be no splash there. Unsafe bad side effects and limited efficacy It’ll be safe to ride it out here for a little bit but this is not the strongest portfolio in eye care.
     

  2. anonymous

    anonymous Guest

    This is a sinking ship… JUST SAY NO TO NK!
     
  3. anonymous

    anonymous Guest

    Focus on Tyrvaya, we have some deadbeat reps and managers that are on the bottom every quarter, they need to go. The Top 30 drive most of the business here, we have territories barely putting up 20 weekly scripts, time to go.
     
  4. anonymous

    anonymous Guest

    This is laughable! Tyrvaya is only doing well there because of the favorable managed market access and the way the reps are “utilizing” the coupons.
     
  5. anonymous

    anonymous Guest

    the garbage is in the north under HZ. Fitting…
     
  6. anonymous

    anonymous Guest

    Plenty of garbage nationally
     
  7. anonymous

    anonymous Guest

    The real garbage is actually PD and his team
     
  8. anonymous

    anonymous Guest

    Mike Campbell couldn’t had a track record of failure
     
  9. anonymous

    anonymous Guest

    Hi NOOOOOEEEELLLLEEEE!
     
  10. anonymous

    anonymous Guest

    Ryzumvi, is there a need for this, don’t think my docs care? Tyrvaya is a dog to sell, hopefully this won’t be.
     
  11. anonymous

    anonymous Guest

    Mydriatics cost about $20, and isurance doesn't pay separately for it, as it's included in the cost of a yearly eye exam (with VSP, etc). So how much is anyone going to pay to undo it?
     
  12. anonymous

    anonymous Guest

    HZ and his New York managers should be fired for hiding the fact that OD’s cannot prescribe a nasal spray for dry eye in New York.

    They all knew about it and lied !!

    Fire HZ and all of the New York Management Team !!
     
  13. anonymous

    anonymous Guest


    This won’t sell well. We will have to hope for broader indications down the road. I myself am not excited about anything for presbyopia down the road. You may think the market has a strong demand for that but it’s showing that it doesn’t.
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    No one lied. You do work for a bunch of idiots though. Tyrvaya is a failure no matter how much they spin the numbers. You are on the Titanic and sinking slowly.
     
  17. anonymous

    anonymous Guest


    I would point that finger at yourself, they’re plenty of ODs prescribing in NY, it’s the excuse of garbage reps and one of the managers Upstate.
     
  18. anonymous

    anonymous Guest

    The update district has been on the bottom since launch. The DBL was promoted. Lol. Funny company with clicks.
    This is typical of MC. Reward loyalty over performance. Leadership insulates themselves with people who won’t wrong them.

    There will be a downsizing soon. The product isn’t making enough money
     
  19. anonymous

    anonymous Guest

    The biggest fraud is Jeff Nau, this train wreck of a franchise lays at his feet. Amateur CEO with zero commercial chops, he’s responsible for this sinking franchise. We get an occasional update from our fearless leader but now his balls are in the purse of Viatris. Calm before the storm
     
  20. anonymous

    anonymous Guest

    We have poor sales, a lack of adoption from HCPs and they think a TV commercial is going to fix it all.

    no one cares about Schirmer data!!!